Altimmune, Inc. (ALT)
- Previous Close
5.76 - Open
5.79 - Bid 4.16 x 200
- Ask 7.23 x 200
- Day's Range
5.60 - 5.89 - 52 Week Range
3.55 - 11.16 - Volume
2,161,784 - Avg. Volume
2,641,021 - Market Cap (intraday)
438.978M - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-1.34 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jan 20, 2017
- 1y Target Est
20.56
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
altimmune.comRecent News: ALT
View MorePerformance Overview: ALT
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALT
View MoreValuation Measures
Market Cap
443.60M
Enterprise Value
313.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
20.45k
Price/Book (mrq)
3.59
Enterprise Value/Revenue
15.67k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.51%
Return on Equity (ttm)
-57.28%
Revenue (ttm)
20k
Net Income Avi to Common (ttm)
-90.24M
Diluted EPS (ttm)
-1.34
Balance Sheet and Cash Flow
Total Cash (mrq)
149.83M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--